Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. reports developments across its global biopharmaceutical business, including prescription medicines, vaccines, biosimilars, sterile injectables, and oncology therapies. Recurring news covers financial results and guidance, commercial portfolio changes within Biopharma, dividend declarations, capital allocation priorities, and product access initiatives for established medicines such as Eliquis.
Company updates also address clinical and regulatory activity across Pfizer's pipeline and marketed products. Recent themes include oncology data presentations, Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma, PADCEV combination regulatory activity in bladder cancer, VYNDAMAX patent litigation settlements, and shareholder meeting communications.
Pfizer (PFE) announced that the CDC's Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for RSV vaccines to include adults aged 50-59 at increased risk of RSV-associated lower respiratory tract disease (LRTD). This expansion specifically includes ABRYSVO®, which received FDA approval in October 2024 for preventing RSV-associated LRTD in at-risk adults aged 18-59.
According to CDC data, approximately 15,000-20,000 RSV-associated hospitalizations occur annually in U.S. adults aged 50-59. The highest risk affects those with underlying conditions such as obesity, cardiovascular disease, diabetes, COPD, asthma, and other chronic or immunocompromising conditions. ABRYSVO currently holds the broadest indication among RSV vaccines, covering older adults, at-risk adults 18 and older, and pregnant women.
Pfizer (NYSE: PFE) has announced the discontinuation of danuglipron, its oral GLP-1 receptor agonist being developed for chronic weight management. While dose-optimization studies of once-daily formulations met key pharmacokinetic objectives, the decision came after a participant experienced potential drug-induced liver injury, which resolved after discontinuing the treatment.
The studies involved over 1,400 participants, with liver enzyme elevations generally aligned with approved agents in the same class. Despite this setback, Pfizer remains committed to advancing treatments for cardiovascular and metabolic diseases, including obesity, through their oral GIPR antagonist candidate and other early-stage obesity programs.
Pfizer (NYSE: PFE) has announced its virtual 2025 Annual Meeting of Shareholders, scheduled for April 24, 2025, at 9:00 a.m. EDT. Shareholders can access the meeting through https://meetnow.global/PFE2025, with login available from 8:45 a.m. EDT.
Participants will need a control number from their proxy card, voting instruction form, or notice to ask questions and vote during the meeting. Questions can be submitted in advance until 5:00 p.m. EDT on April 22. While most shareholders can vote during the meeting, some beneficial owners may need to obtain a legal proxy and pre-register.
The meeting will also be available in listen-only mode without a control number, and a replay will be accessible for up to one year at https://investors.pfizer.com/Investors/Events--Presentations. The virtual format ensures shareholders have comparable rights and opportunities as an in-person meeting.
Pfizer (NYSE: PFE) has received European Commission approval for an expanded indication of its RSV vaccine ABRYSVO®. The authorization now includes prevention of lower respiratory tract disease (LRTD) in adults aged 18-59, extending beyond its previous approval for those 60 and older.
ABRYSVO becomes the first and only RSV vaccine approved in the European Union for non-pregnant adults aged 18-49. The vaccine now offers the broadest RSV indication in the EU, covering both active immunization for adults 18 and older, and passive protection for infants through maternal immunization during pregnancy.
The approval is supported by the phase 3 clinical trial MONeT (NCT05842967), which evaluated the vaccine's safety, tolerability, and immunogenicity in adults 18-59 years with risk factors for RSV-associated LRTD. RSV causes approximately 158,000 adult hospital admissions annually in the EU.
Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, has appointed Jon Coleman as Chief Commercial Officer. Coleman brings over 30 years of global commercial leadership experience and will oversee Dexcom's global commercial organization, including sales, marketing, and customer experience.
Coleman previously served as an executive officer at Masimo (NASDAQ: MASI) for 15 years, where he was president of commercial teams. He managed worldwide hospital sales, OEM, alternate care sales, clinical teams, and customer service. Prior to Masimo, Coleman held leadership positions at Pfizer (NYSE: PFE) Consumer Healthcare, including vice president and general manager of Canada and the Caribbean region, with additional experience in Asia and Latin America.
Throughout his career, Coleman has demonstrated success in scaling operations, developing innovative products, entering new markets, and delivering strong growth performance.
Pfizer (NYSE: PFE) has announced a conference call with investment analysts scheduled for April 29, 2025, at 10:00 a.m. EDT. The call will provide updates on the company's First Quarter 2025 Performance Report, which will be released that morning.
Investors and the public can access the webcast through www.pfizer.com/investors. Participants can also join via phone by dialing 800-456-4352 (US/Canada) or 785-424-1086 (international) using passcode '67619'. The webcast replay and transcript will be available on Pfizer's investor website within 24 hours and remain accessible for 90 days.
Pfizer, with a 175-year legacy, continues its mission of developing innovative medicines and vaccines. The company emphasizes its commitment to quality healthcare, global wellness, and breakthrough therapies that address critical diseases.
ViiV Healthcare has announced groundbreaking results from implementation studies for their HIV prevention injectable Apretude and treatment injectable Cabenuva at CROI 2025. The studies demonstrated remarkable effectiveness with zero HIV acquisitions reported in nearly 4,000 people using Apretude for prevention.
The PILLAR study, involving 201 participants across 17 U.S. clinics, showed zero HIV cases over 12 months, with 72% persistence rate. The ImPrEP CAB Brazil study of 1,447 participants demonstrated superior PrEP coverage with Apretude (96.2%) compared to oral PrEP (64.1%).
For Cabenuva treatment, real-world data from the OPERA analysis (n=2,485) showed 95% of patients maintained viral suppression, with only 1% experiencing confirmed virologic failure. The Trio Health cohort (n=928) similarly demonstrated 95% viral suppression maintenance, with 89% of injections administered on schedule.
ViiV Healthcare announced positive results from its phase IIb EMBRACE study evaluating N6LS (VH3810109), a broadly neutralising antibody for HIV treatment. When administered every four months in combination with monthly cabotegravir long-acting (CAB LA), N6LS effectively maintained viral suppression in HIV patients stable on treatment.
Key findings at the six-month endpoint showed that 96% of participants receiving N6LS 60mg/kg intravenously and 88% receiving 3000mg subcutaneously maintained HIV-1 RNA levels below 50 copies/mL, compared to 96% in the standard-of-care group. The treatment was generally well-tolerated, though subcutaneous administration showed more frequent infusion site reactions (14%) compared to none with IV administration.
Based on these favorable results, ViiV Healthcare will advance development of a six-month IV formulation of N6LS in combination with CAB LA in an EMBRACE part two trial.
ViiV Healthcare announced positive results from two phase IIa studies of investigational HIV therapies at CROI 2025. The studies focused on VH4524184 (VH184), a third-generation integrase inhibitor, and VH4011499 (VH499), a capsid inhibitor, both showing promise as long-acting injectable treatments.
VH184 demonstrated significant antiviral activity across three doses (10mg, 50mg, 300mg) in 22 treatment-naive adults. The 300mg dose achieved the maximum viral load decline of -2.69 log10 copies/mL. All side effects were mild to moderate with no serious adverse events.
VH499 showed positive results in 23 treatment-naive adults across doses of 25mg, 100mg, and 250mg. The highest dose (250mg) achieved a -2.2 log10 copies/mL decrease in HIV-1 viral load. The treatment was well-tolerated with only mild to moderate adverse events reported.
FoRx Therapeutics has appointed Dr. Jens Würthner as Chief Medical Officer, bringing over 20 years of clinical development expertise in oncology therapeutics. Dr. Würthner's experience includes successful drug development at companies like Novartis, GlaxoSmithKline, AstraZeneca, and ADC Therapeutics, where he oversaw the development of loncastuximab teserine (Zynlonta).
The company also provided an update on FORX-428, their lead development candidate targeting solid tumors. This PARG (Poly(ADP-ribose) glycohydrolase) inhibitor is progressing toward IND submission by mid-2025. Recent developments include:
- Completion of GLP toxicological testing
- Identification of predictive biomarkers for patient selection
- Promising animal studies showing strong anti-tumor efficacy and good tolerability